GlassScriptPhysician profile
Ann Ledet
NPI 1104068824
$2,991.22
in general payments reported to CMS, 2019-2025
30 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $348 · 2023: $768 · 2024: $1,568 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.34 |
| Education | $208.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $621.17 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $586.14 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Astellas Pharma US INC | $178.43 | 2023-2024 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $176.94 | 2022-2024 | Enhertu |
| Amgen INC. | $157.18 | 2023-2024 | Evenity, Prolia, Lumakras |
| Emd Serono, INC. | $146.19 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $140.27 | 2022-2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $118.96 | 2023-2025 | |
| Janssen Biotech, INC. | $98.31 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Abbvie INC. | $79.83 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.22 | 2023-2025 | |
| Genzyme Corporation | $65.66 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.08 | 2023-2024 | Ninlaro, Alunbrig |
| Genentech USA, INC. | $62.69 | 2024-2025 | Polivy, Columvi, Tecentriq Hybreza |
| Jazz Pharmaceuticals INC. | $53.05 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.33 | 2023 | |
| Alexion Pharmaceuticals, INC. | $33.02 | 2023-2024 | Ultomiris |
| Eisai INC. | $27.49 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $27.40 | 2024 | Somatuline Depot, Onivyde |
| Bard Peripheral Vascular, INC. | $26.83 | 2023 | Rotarexs 6 F X 135 Cm, Lifestream |
| Adaptive Biotechnologies Corporation | $26.04 | 2024 | Clonoseq |
| Stemline Therapeutics INC. | $25.53 | 2024 | Orserdu |
| Exelixis INC. | $25.01 | 2024 | Cabometyx |
| Janssen Pharmaceuticals, INC | $24.23 | 2023 | Xarelto |
| Beigene USA, INC. | $23.16 | 2024 | Brukinsa |
| Tersera Therapeutics LLC | $20.92 | 2022 | |
| Pharmacosmos Therapeutics INC. | $20.77 | 2024 | Cosela |
| Incyte Corporation | $19.60 | 2024 | Jakafi |
| Celgene Corporation | $15.56 | 2024 | Opdualag |
| E.R. Squibb & Sons, L.L.C. | $13.21 | 2024 | Opdualag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Ledet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.